These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 19576651)
1. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Buti M; Brosa M; Casado MA; Rueda M; Esteban R J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Lui YY; Tsoi KK; Wong VW; Kao JH; Hou JL; Teo EK; Mohamed R; Piratvisuth T; Han KH; Mihm U; Wong GL; Chan HL Antivir Ther; 2010; 15(2):145-55. PubMed ID: 20386069 [TBL] [Abstract][Full Text] [Related]
3. Entecavir for the treatment of chronic hepatitis B infection. Shepherd J; Gospodarevskaya E; Frampton G; Cooper K Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Wu B; Li T; Chen H; Shen J Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341 [TBL] [Abstract][Full Text] [Related]
5. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea]. Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783 [TBL] [Abstract][Full Text] [Related]
6. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China]. Larry L; Lu XZ; Alison T Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808 [TBL] [Abstract][Full Text] [Related]
7. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. Lee KK; Wu DB; Chow PY; Lee VW; Li H J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402 [TBL] [Abstract][Full Text] [Related]
8. Telbivudine for the treatment of chronic hepatitis B infection. Hartwell D; Jones J; Harris P; Cooper K Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025 [TBL] [Abstract][Full Text] [Related]
9. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607 [TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine. Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. Jones J; Colquitt J; Shepherd J; Harris P; Cooper K Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800 [TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. He J; Bowen JM; Xie F; Goeree R Value Health; 2012; 15(6):894-906. PubMed ID: 22999140 [TBL] [Abstract][Full Text] [Related]
17. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis. Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357 [TBL] [Abstract][Full Text] [Related]
19. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. Petersen J; Ratziu V; Buti M; Janssen HL; Brown A; Lampertico P; Schollmeyer J; Zoulim F; Wedemeyer H; Sterneck M; Berg T; Sarrazin C; Lutgehetmann M; Buggisch P J Hepatol; 2012 Mar; 56(3):520-6. PubMed ID: 22037226 [TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]